{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:41:11Z","timestamp":1790444471459,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clml.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:31:52Z","timestamp":1654561912000},"page":"e893-e897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["PD-1 Blockade After Avelumab in Relapsed\/Refractory Classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-3274","authenticated-orcid":false,"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew G.","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-4288","authenticated-orcid":false,"given":"James","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-5046","authenticated-orcid":false,"given":"Eileen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.06.004_bib0001","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.004_bib0003","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.004_bib0004","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124866","article-title":"Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged \u226560 years","volume":"134","author":"Yasenchak","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.004_bib0006","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/OP.20.01020","article-title":"PD-1 blockade in classic Hodgkin lymphoma","volume":"17","author":"Ansell","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2022.06.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2437_54","article-title":"Blockade of the PD-1 checkpoint with anti\u2013PD-l1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL)","volume":"35","author":"Chen","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.06.004_bib0008","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.06.004_bib0009","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.06.004_bib0010","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.004_bib0011","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.06.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127280","article-title":"Three-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed\/refractory classic Hodgkin lymphoma","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.004_bib0013","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-021-04429-8","article-title":"Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma","volume":"100","author":"Fedorova","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.06.004_bib0014","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3324\/haematol.2019.242529","article-title":"Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation","volume":"105","author":"Manson","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.06.004_bib0015","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00262-020-02832-0","article-title":"Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma","volume":"70","author":"Glutsch","year":"2021","journal-title":"Cancer Immunol Immunother"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:46:59Z","timestamp":1729856819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2152265022001859"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.06.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1 Blockade After Avelumab in Relapsed\/Refractory Classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}